CN102015683B - 取代的吲哚衍生物 - Google Patents
取代的吲哚衍生物 Download PDFInfo
- Publication number
- CN102015683B CN102015683B CN200980115064.3A CN200980115064A CN102015683B CN 102015683 B CN102015683 B CN 102015683B CN 200980115064 A CN200980115064 A CN 200980115064A CN 102015683 B CN102015683 B CN 102015683B
- Authority
- CN
- China
- Prior art keywords
- base
- methyl
- dimethylamino
- ethyl
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- MVCIMEGPCAVHOK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1C(O)=O)c2c1cccc2)=O Chemical compound CC(C)(C)OC(N(CC1C(O)=O)c2c1cccc2)=O MVCIMEGPCAVHOK-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)(C)OC(N(CC1C(OC)=*)c2c1cccc2)=O Chemical compound CC(C)(C)OC(N(CC1C(OC)=*)c2c1cccc2)=O 0.000 description 1
- VOWZQOSRBMJMJM-UHFFFAOYSA-N CC(C)(C)OC([n]1c2ccccc2c(C(OC)=O)c1)=O Chemical compound CC(C)(C)OC([n]1c2ccccc2c(C(OC)=O)c1)=O VOWZQOSRBMJMJM-UHFFFAOYSA-N 0.000 description 1
- QXAUTQFAWKKNLM-UHFFFAOYSA-N COC(c1c[nH]c2ccccc12)=O Chemical compound COC(c1c[nH]c2ccccc12)=O QXAUTQFAWKKNLM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08003238 | 2008-02-22 | ||
| EP08003238.6 | 2008-02-22 | ||
| PCT/EP2009/001232 WO2009103552A1 (en) | 2008-02-22 | 2009-02-20 | Substituted indole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102015683A CN102015683A (zh) | 2011-04-13 |
| CN102015683B true CN102015683B (zh) | 2015-08-05 |
Family
ID=39449548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980115064.3A Expired - Fee Related CN102015683B (zh) | 2008-02-22 | 2009-02-20 | 取代的吲哚衍生物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090215828A1 (enExample) |
| EP (1) | EP2254883B1 (enExample) |
| JP (1) | JP5635914B2 (enExample) |
| CN (1) | CN102015683B (enExample) |
| AR (1) | AR070398A1 (enExample) |
| AU (1) | AU2009216920B2 (enExample) |
| CA (1) | CA2716270C (enExample) |
| CL (1) | CL2009000404A1 (enExample) |
| IL (1) | IL207684A (enExample) |
| MX (1) | MX2010009045A (enExample) |
| PE (1) | PE20091490A1 (enExample) |
| RU (1) | RU2500677C2 (enExample) |
| WO (1) | WO2009103552A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
| CN104311472B9 (zh) | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| US8415484B2 (en) | 2008-08-27 | 2013-04-09 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| TW201020247A (en) * | 2008-11-06 | 2010-06-01 | Gruenenthal Gmbh | Substituierte disulfonamide |
| SG10201500639TA (en) | 2010-01-27 | 2015-03-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| EP2542554B1 (en) | 2010-03-03 | 2015-11-04 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| PT2566327T (pt) | 2010-05-07 | 2017-05-26 | Glaxosmithkline Llc | Indoles |
| ES2600161T3 (es) | 2011-11-04 | 2017-02-07 | Glaxosmithkline Intellectual Property (No. 2) Limited | Compuestos para uso en el tratamiento de enfermedades mediadas por linfocitos T |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| ES2995737T3 (en) | 2015-01-06 | 2025-02-11 | Arena Pharm Inc | Compound for use in treating conditions related to the s1p1 receptor |
| MA42807A (fr) | 2015-06-22 | 2018-07-25 | Arena Pharm Inc | Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1 |
| BR112019009731A2 (pt) * | 2016-11-18 | 2019-08-13 | Merck Sharp & Dohme | composto, composição farmacêutica, uso de um composto, e, método de tratamento |
| WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| US11993571B2 (en) * | 2017-03-10 | 2024-05-28 | Rutgers, The State University Of New Jersey | Indole derivatives as efflux pump inhibitors |
| EP3801459B1 (en) | 2018-06-06 | 2024-08-07 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| WO2020051378A1 (en) | 2018-09-06 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| US20240408064A1 (en) * | 2021-10-15 | 2024-12-12 | Genetolead Inc. | Ras inhibitors, compositions and methods of use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107329A (en) * | 1995-06-06 | 2000-08-22 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
| WO2003037863A2 (de) * | 2001-10-29 | 2003-05-08 | Grünenthal GmbH | Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung |
| WO2004043949A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | 4-substituierte 1-aminocyclohexan-derivate zur verwendung als orl1-rezeptor- und mu-opiat-rezeptor-liganden |
| WO2004043909A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Cyclohexyl-harnstoff-derivate |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1586817A (en) * | 1977-12-01 | 1981-03-25 | Wyeth John & Brother Ltd | Indole derivatives |
| AU1930801A (en) * | 1999-12-20 | 2001-07-03 | Eli Lilly And Company | Indole derivatives for the treatment of depression and anxiety |
| KR20050045927A (ko) * | 2003-11-12 | 2005-05-17 | 주식회사 엘지생명과학 | 멜라노코틴 수용체의 항진제 |
| GB0510810D0 (en) * | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20070219214A1 (en) * | 2006-02-01 | 2007-09-20 | Solvay Pharmaceuticals Gmbh | Dual NK2/NK3-antagonists, pharmaceutical compositions comprising them, and processes for their preparation |
| RU2008135123A (ru) * | 2006-02-01 | 2010-03-10 | Зольвай Фармасьютикалз Гмбх (De) | Новые двойные антагонисты nk2/nk3, содержащие их фармацевтические композиции и способы их получения |
| EA200901212A1 (ru) * | 2007-03-29 | 2010-04-30 | Новартис Аг | 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний |
| AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
-
2009
- 2009-02-16 AR ARP090100544A patent/AR070398A1/es not_active Application Discontinuation
- 2009-02-19 US US12/388,977 patent/US20090215828A1/en not_active Abandoned
- 2009-02-20 EP EP09713555.2A patent/EP2254883B1/en not_active Not-in-force
- 2009-02-20 PE PE2009000247A patent/PE20091490A1/es not_active Application Discontinuation
- 2009-02-20 RU RU2010138838/04A patent/RU2500677C2/ru not_active IP Right Cessation
- 2009-02-20 MX MX2010009045A patent/MX2010009045A/es active IP Right Grant
- 2009-02-20 CL CL2009000404A patent/CL2009000404A1/es unknown
- 2009-02-20 AU AU2009216920A patent/AU2009216920B2/en not_active Ceased
- 2009-02-20 JP JP2010547116A patent/JP5635914B2/ja not_active Expired - Fee Related
- 2009-02-20 WO PCT/EP2009/001232 patent/WO2009103552A1/en not_active Ceased
- 2009-02-20 CN CN200980115064.3A patent/CN102015683B/zh not_active Expired - Fee Related
- 2009-02-20 CA CA2716270A patent/CA2716270C/en not_active Expired - Fee Related
-
2010
- 2010-08-19 IL IL207684A patent/IL207684A/en not_active IP Right Cessation
-
2012
- 2012-12-11 US US13/710,604 patent/US9206156B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107329A (en) * | 1995-06-06 | 2000-08-22 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
| WO2003037863A2 (de) * | 2001-10-29 | 2003-05-08 | Grünenthal GmbH | Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung |
| WO2004043949A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | 4-substituierte 1-aminocyclohexan-derivate zur verwendung als orl1-rezeptor- und mu-opiat-rezeptor-liganden |
| WO2004043909A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Cyclohexyl-harnstoff-derivate |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009103552A1 (en) | 2009-08-27 |
| RU2010138838A (ru) | 2012-03-27 |
| US20090215828A1 (en) | 2009-08-27 |
| US9206156B2 (en) | 2015-12-08 |
| MX2010009045A (es) | 2010-09-24 |
| EP2254883A1 (en) | 2010-12-01 |
| AU2009216920A1 (en) | 2009-08-27 |
| RU2500677C2 (ru) | 2013-12-10 |
| PE20091490A1 (es) | 2009-09-26 |
| HK1149762A1 (en) | 2011-10-14 |
| CN102015683A (zh) | 2011-04-13 |
| JP2011512374A (ja) | 2011-04-21 |
| IL207684A (en) | 2015-08-31 |
| CA2716270A1 (en) | 2009-08-27 |
| US20130116283A1 (en) | 2013-05-09 |
| EP2254883B1 (en) | 2014-11-26 |
| AU2009216920B2 (en) | 2013-06-13 |
| AR070398A1 (es) | 2010-03-31 |
| CL2009000404A1 (es) | 2010-04-16 |
| IL207684A0 (en) | 2010-12-30 |
| JP5635914B2 (ja) | 2014-12-03 |
| CA2716270C (en) | 2016-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102015683B (zh) | 取代的吲哚衍生物 | |
| ES2309373T3 (es) | Derivados de 1-aminociclohexano-4-sustituidos utiles como ligandos del receptor orl1 y del receptor mu-opioide. | |
| US6998409B2 (en) | Substituted 2-pyridine cyclohexane-1,4-diamine compounds | |
| JP5366832B2 (ja) | スピロ環式シクロヘキサン誘導体 | |
| CN1972929A (zh) | 治疗偏头痛的杂环类cgrp拮抗剂 | |
| US7368470B2 (en) | Substituted 3-pyrrolidine-indole derivatives | |
| CN101356174B (zh) | 吲哚-3-基-羰基-螺-哌啶衍生物 | |
| US20110009379A1 (en) | Indolinone compound | |
| CA2563017C (en) | Substituted cyclohexylacetic acid derivatives | |
| JP4208139B2 (ja) | 置換された４−アミノシクロヘキサノール | |
| JP5650637B2 (ja) | （ヘテロ−）アリール−シクロヘキサン誘導体 | |
| CA2738749A1 (en) | Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics | |
| JP5492189B2 (ja) | Ｃｃｒ１０アンタゴニストである２−スルホニルアミノ−４−ヘテロアリールブチロアミド | |
| CN101547923A (zh) | 作为via受体拮抗剂的螺环-哌啶衍生物 | |
| CN101273046B (zh) | 作为加压素受体拮抗剂的吲哚-3-基-羰基氮杂螺环衍生物 | |
| HK1149762B (en) | Substituted indole derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150805 Termination date: 20190220 |